Euroopa Liit -
eesti -
EMA (European Medicines Agency)
sutent
pfizer limited - sunitiniib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastilised ained - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
Eesti -
eesti -
Ravimiamet
sunitinib sandoz kõvakapsel
sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 25mg 110tk; 25mg 28tk; 25mg 56tk; 25mg 30tk; 25mg 100tk; 25mg 90tk; 25mg 70tk; 25mg 98tk; 25mg 84tk
Eesti -
eesti -
Ravimiamet
sunitinib sandoz kõvakapsel
sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 50mg 30tk
Eesti -
eesti -
Ravimiamet
sunitinib sandoz kõvakapsel
sandoz pharmaceuticals d.d. - sunitiniib - kõvakapsel - 12,5mg 30tk